Cartesian Therapeutics
RNAC
67 hedge funds and large institutions have $37.2M invested in Cartesian Therapeutics in 2025 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 22 increasing their positions, 17 reducing their positions, and 16 closing their positions.
29% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 17
16% more call options, than puts
Call options by funds: $309K | Put options by funds: $266K
6% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 16
1% less funds holding
Funds holding: 68 → 67 (-1)
3.2% less ownership
Funds ownership: 23.05% → 19.85% (-3.2%)
39% less capital invested
Capital invested by funds: $60.9M → $37.2M (-$23.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PFM
Privium Fund Management
Amsterdam,
Netherlands
|
+$1.39M |
| 2 |
Millennium Management
New York
|
+$1.12M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$801K |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$755K |
| 5 |
Two Sigma Investments
New York
|
+$738K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$6.38M |
| 2 |
SL
Siren LLC
Greenwich,
Connecticut
|
-$5.76M |
| 3 |
MB
MPM BioImpact
Boston,
Massachusetts
|
-$3.88M |
| 4 |
BlackRock
New York
|
-$321K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$286K |
RNAC Hedge Fund Activity: Q4 2025 in Review
67 of the 8,228 institutional investors tracked by Wall St. Rank reported a position in Cartesian Therapeutics (RNAC) for Q4 2025, worth a combined $37.2M — down 39% from $60.9M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of RNAC and 15 opened new positions — a net loss of 1 holder — while 17 trimmed existing stakes and 22 added.
The largest buyer was Privium Fund Management, opening a new position worth an estimated $1.39M. The largest seller was Fidelity Investments, cutting an estimated $6.38M.
- 67 institutional investors held Cartesian Therapeutics (RNAC) as of Q4 2025, down from 68 in Q3 2025.
- Funds reported $37.2M of Cartesian Therapeutics stock for Q4 2025, down 39% quarter-over-quarter.
- 15 funds opened new Cartesian Therapeutics positions in Q4 2025 and 16 closed out, a net change of -1 holder.
- The largest Cartesian Therapeutics buyer in Q4 2025 was Privium Fund Management, an estimated $1.39M added.
- The largest Cartesian Therapeutics seller in Q4 2025 was Fidelity Investments, an estimated $6.38M sold.
Based on aggregated 13F filings for Q4 2025.